Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

49Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100,000 patient years followup, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 x higher risk of subsequent MDS/AML compared to that seen in the general population. (C) 2000 Cancer Research Campaign.

Cite

CITATION STYLE

APA

Saso, R., Kulkarni, S., Mitchell, P., Treleaven, J., Swansbury, G. J., Mehta, J., … Powles, T. (2000). Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. British Journal of Cancer, 83(1), 91–94. https://doi.org/10.1054/bjoc.2000.1196

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free